Catalent To Purchase Bristol-Myers Squibb’s Biologics And Oral Dose Site In Anagni, Italy
The most choices and deepest expertise – across the pulmonary and nasal market
On June 19, Catalent announced it had agreed to purchase Bristol-Myers Squibb’s premier biologics and oral dose form manufacturing facility in Anagni, Italy.
Through the years, Anagni facility has served as one of the primary launch facilities for new medicines from Bristol-Myers Squibb that have helped millions of patients in the fight against serious diseases such as cancer and cardiovascular disease. The facility has a demonstrated track record for innovation, efficiency and accelerated product launches, including flagship medicines such as SPRYCEL® (dasatinib), BARACLUDE® (entecavir), REYATAZ® (atazanavir ), YERVOY® (ipilimumab) and OPDIVO® (nivolumab).
Upon closing, this state-of-the-art facility for late phase tech transfers and new launches will provide Catalent customers access to new capabilities and additional capacity in Europe.
Read the press release.
For Biologics, Anagni will provide:
- Sterile fill/finish, including Biologics drug product
- Isolator technology
- Automated inspection, packaging and warehousing
- World class expertise in global product launches
The Anagni plant will complement Catalent’s existing European Biologics capabilities in Brussels, Belgium, providing process development, sterile fill/finish and primary & secondary packaging for pre-filled syringe, and our Clinical Supply sites in the United Kingdom and Germany.
For Oral Delivery, Anagni will provide:
- End-to-end oral dose development to commercial manufacturing
- Flexible manufacturing with turnkey packaging, including sterilization
- Unique 48-hour fast-response packaging solutions from order to shipment
- World-class expertise in global product launches
The Anagni plant will complement Catalent’s existing European oral dose development capabilities in Nottingham, U.K., complex modified release development and manufacturing in Schorndorf, Germany, and Zydis® fast dissolving tablets development and manufacturing in Swindon, U.K., providing ample oral dose form capacity and secondary packaging solutions.
Contact us to discuss a potential tech transfer today!